Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients.

ABSTRACT:

Background

The results of Aspirin prevention of colorectal adenomas in patients with familial adenomatous polyposis (FAP) are controversial.

Methods

We conducted a biomarker-based clinical study in eight FAP patients treated with enteric-coated low-dose Aspirin (100 mg daily for three months) to explore whether the drug targets mainly platelet cyclooxygenase (COX)-1 or affects extraplatelet cellular sources expressing COX-isozymes and/or off-target effects in colorectal adenomas.

Results

In FAP patients, low-dose Aspirin-acetylated platelet COX-1 at Serine529 (>70%) was associated with an almost complete inhibition of platelet thromboxane (TX) B₂ generation ex vivo (serum TXB₂). However, enhanced residual urinary 11-dehydro-TXB₂ and ur

SUBMITTER: Lanas A 

PROVIDER: S-EPMC10177499 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature